Rixensart, Belgium

Demostene Sifakakis

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Glaxosmithkline Biologicals Sa. Active years: 2024-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Demostene Sifakakis: Innovator in Adjuvant Manufacturing

Introduction

Demostene Sifakakis is a notable inventor based in Rixensart, Belgium. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of adjuvants. With a total of 2 patents to his name, Sifakakis continues to push the boundaries of innovation in his area of expertise.

Latest Patents

One of his latest patents is titled "Methods for Manufacturing an Adjuvant." This invention relates to compositions and methods for manufacturing an adjuvant comprising a saponin using a microfluidic device. The innovative approach aims to enhance the efficiency and effectiveness of adjuvant production, which is crucial for vaccine development.

Career Highlights

Demostene Sifakakis is currently employed at GlaxoSmithKline Biologicals SA, a leading company in the biopharmaceutical sector. His work at this esteemed organization allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Throughout his career, Sifakakis has worked alongside talented colleagues such as Loic Le Gourrierec and Pol Harvengt. These collaborations have fostered a creative environment that encourages the exchange of ideas and the advancement of innovative solutions.

Conclusion

Demostene Sifakakis is a prominent figure in the realm of adjuvant manufacturing, with a focus on enhancing vaccine efficacy. His contributions through patents and collaborations highlight his commitment to innovation in the pharmaceutical industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…